Evidence map›Paper›PMID 39805870›Full record

ArticleScientific reports2025

The burden of prostate cancer in the North Africa and Middle East Region from 1990 to 2021.

Saeid Safiri, Ali Shamekh, Kamaleddin Hassanzadeh, Asra Fazlollahi, Mark J M Sullman, Mortaza Raeisi, Ali-Asghar Kolahi

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. ComprehensiveFrontiers in cell and developmental biology · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Saeid SafiriClinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Ali ShamekhSocial Determinants of Health Research Center, Department of Community Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Kamaleddin HassanzadehDepartment of Urology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Asra FazlollahiAging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Mark J M SullmanDepartment of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus.
Mortaza RaeisiHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Ali-Asghar KolahiSocial Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. a.kolahi@sbmu.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer ranks among the most prevalent malignancies affecting males globally. This study sought to document the incidence, deaths and disability-adjusted life-years (DALYs) that were due to prostate cancer in the Middle East and North Africa (MENA) region, and its 21 countries, from 1990 to 2021. We analysed publicly accessible data from the Global Burden of Disease 2021 study to present findings on the incidence, deaths, and disability-adjusted life years (DALYs) associated with prostate cancer. These metrics were reported as counts and age-standardised rates, each accompanied by 95% uncertainty intervals. In 2021, the age-standardised incidence of prostate cancer in the region was 27.4 per 100,000 population, representing a 125.1% increase from 1990. The age-standardised mortality rate was 10.1, and the age-standardised DALY rate was 173.6, neither of which showed significant increases since 1990. Qatar recorded the highest age-standardised DALY rate in 2021, while Algeria had the lowest. The largest number of incident cases, deaths, and DALYs in 2021 were found in the 65-69, 80-84, and 70-74 age groups, respectively. Additionally, from 1990 to 2021, the burden of prostate cancer largely increased with the socio-demographic index (SDI) at the regional level. The burden of prostate cancer in the MENA region rose markedly between 1990 and 2021. Further studies into the underlying causes of this increasing incidence are essential to devise effective strategies for the early detection and prevention of the disease.

Indexed as

Prostatic NeoplasmsAdultAfrica, NorthernAgedAged, 80 and overCost of IllnessDisability-Adjusted Life YearsGlobal Burden of DiseaseHumansIncidenceMaleMiddle AgedMiddle EastQuality-Adjusted Life YearsDisability-adjusted life-yearsDisease burdenEpidemiologyIncidenceMiddle East and North AfricaMortalityProstate Cancer

Identifiers

PMID39805870
PMCPMC11731011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.